PROTECTIVE ROLE OF NANOCONJUGATED VANCOMYCIN AGAINST VANCOMYCIN SENSITIVE STAPHYLOCOCCUS AUREUS INDUCED OXIDATIVE STRESS AND DNA DAMAGE

被引:3
|
作者
Chakraborty, Subhankari Prasad [1 ]
Pramanik, Panchanan [2 ]
Roy, Somenath [1 ]
机构
[1] Vidyasagar Univ, Dept Human Physiol Community Hlth, Immunol & Microbiol Lab, Midnapore 721102, W Bengal, India
[2] Indian Inst Technol, Dept Chem, Nanomat Lab, Kharagpur 721302, W Bengal, India
关键词
VSSA; Nitrate generation; Lipid peroxidation; Antioxidant enzyme; DNA fragmentation;
D O I
10.13040/IJPSR.0975-8232.3(2).405-15
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Staphylococcus aureus causes a wide range of infection such as skin and soft tissue infection to life threatening disease like respiratory tract infection, musculoskeletal infection, endocarditis and urinary tract infection. The aim of the present study was to evaluate the possible protective effects of nanoconjugated vancomycin against VSSA infection on select makers of oxidative damage and antioxidant status in liver, kidney and spleen. A coagulase positive VSSA strain was used for this study. VSSA infection was developed in Swiss mice by intraperitoneal injection of 5 x 10(6) CFU/ml bacterial solutions. Nanoconjugated vancomycin was treated to VSSA infected mice at a dose of 100 mg/kg b.w/day for 10 days. After decapitation, liver, kidney and spleen were excised from control and experimental groups, homogenized and used for different biochemical estimation. Nitrate level, myeloperoxidse activity, lipid peroxidation, protein oxidation, oxidized glutathione, DNA fragmentation level were increased significantly (p<0.05) in liver, kidney and spleen of VSSA infected group as compared to control group, and reduced glutathione level, activity of antioxidant enzymes (SOD and CAT), glutathione dependent enzymes (GPx, GR and GST) were decreased significantly (p<0.05); which were increased or decreased significantly (p<0.05) near to normal in nanoconjugated vancomycin treated group. These finding suggests the potential use and beneficial role of nanoconjugated vancomycin against VSSA infection induced oxidative stress and DNA damage in liver, kidney and spleen.
引用
收藏
页码:405 / 415
页数:11
相关论文
共 50 条
  • [31] Comparative Analysis of Virulence and Toxin Expression of Vancomycin-Intermediate and Vancomycin-Sensitive Staphylococcus aureus Strains
    Jin, Ye
    Yu, Xiao
    Zhang, Shuntian
    Kong, Xiaoyang
    Chen, Weiwei
    Luo, Qixia
    Zheng, Beiwen
    Xiao, Yonghong
    FRONTIERS IN MICROBIOLOGY, 2020, 11
  • [32] Vancomycin and Piperacillin-Tazobactam Against Methicillin-Resistant Staphylococcus aureus and Vancomycin-Intermediate Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic Model
    Dilworth, Thomas J.
    Leonard, Steve N.
    Vilay, A. Mary
    Mercier, Renee-Claude
    CLINICAL THERAPEUTICS, 2014, 36 (10) : 1334 - 1344
  • [33] The Role of β-Glycosylated Wall Teichoic Acids in the Reduction of Vancomycin Susceptibility in Vancomycin-Intermediate Staphylococcus aureus
    Hort, Michael
    Bertsche, Ute
    Nozinovic, Senada
    Dietrich, Alina
    Schroetter, Anne Sophie
    Mildenberger, Laura
    Axtmann, Katharina
    Berscheid, Anne
    Bierbaum, Gabriele
    MICROBIOLOGY SPECTRUM, 2021, 9 (02):
  • [34] Oxidative stress resistance and fitness-compensatory response in vancomycin-intermediate Staphylococcus aureus (VISA)
    Tan, Xin-Ee
    Neoh, Hui-min
    Cui, Longzhu
    Hiramatsu, Keiichi
    Jamal, Rahman
    CANADIAN JOURNAL OF MICROBIOLOGY, 2019, 65 (08) : 623 - 628
  • [35] β-Lactams Enhance Vancomycin Activity against Methicillin-Resistant Staphylococcus aureus Bacteremia Compared to Vancomycin Alone
    Dilworth, Thomas J.
    Ibrahim, Omar
    Hall, Pamela
    Sliwinski, Jora
    Walraven, Carla
    Mercier, Renee-Claude
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (01) : 102 - 109
  • [36] Cephem-induced vancomycin resistance observed in phenotypically methicillin-sensitive Staphylococcus aureus isolated from a patient treated with vancomycin and cephems
    Iwakawa, K
    Kizu, J
    Hosaka, Y
    Yamamoto, K
    JAPANESE JOURNAL OF INFECTIOUS DISEASES, 2000, 53 (04) : 167 - 169
  • [37] Combination effect of vancomycin and β-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin
    Aritaka, N
    Hanaki, H
    Cui, LZ
    Hiramatsu, K
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (04) : 1292 - 1294
  • [38] Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA)
    Leonard, Steven N.
    Szeto, Yong G.
    Zolotarev, Maria
    Grigoryan, Ilona V.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2011, 37 (06) : 558 - 561
  • [39] Novel vancomycin-peptide conjugate as potent antibacterial agent against vancomycin-resistant Staphylococcus aureus
    Jelinkova, Pavlina
    Splichal, Zbynek
    Jimenez, Ana Maria Jimenez
    Haddad, Yazan
    Mazumdar, Aninda
    Sur, Vishma Pratap
    Milosavljevic, Vedran
    Kopel, Pavel
    Buchtelova, Hana
    Guran, Roman
    Zitka, Ondrej
    Richtera, Lukas
    Hegerova, Dagmar
    Heger, Zbynek
    Moulick, Amitava
    Adam, Vojtech
    INFECTION AND DRUG RESISTANCE, 2018, 11 : 1807 - 1817
  • [40] Synergistic interaction between arbekacin and vancomycin, teicoplanin, or rifampin against vancomycin-resistant Staphylococcus aureus (VRSA)
    Heo, ST
    Kim, S
    Lee, JY
    Jung, SI
    Kim, YS
    Oh, WS
    Peck, KR
    Lee, NY
    Song, JH
    CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1180 - 1180